Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients

被引:4
|
作者
Wang, Miao [1 ,2 ]
Duan, Bao-ling [2 ]
Yuan, Yin-jin [3 ]
Su, Xia [1 ]
Zheng, Hang [1 ]
Wang, Fu-sheng [2 ]
Sun, He [1 ]
机构
[1] Tianjin Univ, Sch Pharmaceut Sci & Technol, 92 Weijin Rd, Tianjin 300072, Peoples R China
[2] North China Pharmaceut Grp Corp, New Drug Res & Dev Ctr, Natl Engn Res Ctr Microbial Med, Shijiazhuang, Hebei, Peoples R China
[3] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China
关键词
renal transplant patients; healthy subjects; population pharmacokinetics; sirolimus; cyclosporine; CLINICAL PHARMACOKINETICS; PEDIATRIC-PATIENTS; RAPAMYCIN; SAFETY; CYCLOSPORINE; VOLUNTEERS; RECIPIENTS; REJECTION; EFFICACY; ADULT;
D O I
10.5414/CP202499
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To identify the factors affecting the pharmacokinetics (PKs) of sirolimus in healthy Chinese subjects and renal transplant patients. Methods: A population PK model of sirolimus was constructed using dense data from 22 healthy volunteers and sparse data from 105 renal transplant patients. Results: The data were well described by a two-compaitment model with first-order absorption. The estimates of absorption rate constant (Ka), clearance (CL/F), and central volume of distribution (V2/F) were 0.24 h(-1), 8.81 L/h, and 676 L, respectively. The CL/F in renal transplant patients was 45.5% lower than that in healthy subjects. Based on the final model, CL/F decreased significantly with increasing cyclosporine (CsA) daily dose and age. A decrease of 7.3% in CL/F for every 100-mg increase in the CsA daily dose and a decrease of 34.2% in CL/F for every 20-year increase in age was observed. Moreover, V2/F increased significantly with increasing serum creatinine in our study. However, the range of serum creatinine concentration and the interindividual variability for V2/F are large. Conclusion: This is the first study to characterize the population PKs of sirolimus using a two-compartment model in healthy Chinese subjects and renal transplant patients. A decrease of 7.3% in the sirolimus CL/F for every 100-mg increase in the CsA daily dose and a decrease of 34.2% in the sirolimus CL/F for every 20-year increase in age was observed, which allowed us to better optimize sirolimus dosing regimens in Chinese renal transplant patients.
引用
收藏
页码:433 / 441
页数:9
相关论文
共 50 条
  • [31] Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
    Morelon, E
    Stern, M
    Israël-Biet, D
    Corréas, JM
    Danel, C
    Mamzer-Bruneel, MF
    Peraldi, MN
    Kreis, H
    TRANSPLANTATION, 2001, 72 (05) : 787 - 790
  • [32] Population Pharmacokinetic Analysis of Istradefylline in Healthy Subjects and in Patients With Parkinson's Disease
    Knebel, William
    Rao, Niranjan
    Uchimura, Tatsuo
    Mori, Akihisa
    Fisher, Jeannine
    Gastonguay, Marc R.
    Chaikin, Philip
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (01): : 40 - 52
  • [33] Population Pharmacokinetic Analysis of Tesamorelin in HIV-Infected Patients and Healthy Subjects
    Gonzalez-Sales, Mario
    Barriere, Olivier
    Tremblay, Pierre Olivier
    Nekka, Fahima
    Mamputu, Jean-Claude
    Boudreault, Sylvie
    Tanguay, Mario
    CLINICAL PHARMACOKINETICS, 2015, 54 (03) : 285 - 294
  • [34] Population pharmacokinetic modelling and simulation of tafamidis in healthy subjects and patients with transthyretin amyloidosis
    Huh, Yeamin
    Riley, Steve
    Harnisch, Lutz
    Nicholas, Timothy
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (09) : 3574 - 3587
  • [35] Population Pharmacokinetic Model for Levomilnacipran in Healthy Subjects and Patients with Major Depressive Disorder
    Carrothers, Timothy J.
    Khariton, Tatiana
    Chen, ChunLin
    Periclou, Antonia
    Chen, Laishun
    Green, Michelle
    Bax, Leon
    Kastrissios, Helen
    Ghahramani, Parviz
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S61 - S63
  • [36] Population Pharmacokinetic Analysis of Tesamorelin in HIV-Infected Patients and Healthy Subjects
    Mario González-Sales
    Olivier Barrière
    Pierre Olivier Tremblay
    Fahima Nekka
    Jean-Claude Mamputu
    Sylvie Boudreault
    Mario Tanguay
    Clinical Pharmacokinetics, 2015, 54 : 285 - 294
  • [37] Population pharmacokinetic modeling of ilaprazole in healthy subjects and patients with duodenal ulcer in China
    Yu, Mengyang
    Liu, Shupeng
    Wu, Xiaofei
    Wang, Hongyun
    FRONTIERS IN PHARMACOLOGY, 2024, 14
  • [38] Steady-State Pharmacokinetics of Sirolimus in Stable Adult Chinese Renal Transplant Patients
    Wang, Huifen Faye
    Qiu, Feng
    Wu, Xiongfe
    Fang, Juanzhi
    Crownover, Penelope
    Korth-Bradley, Joan
    Schulman, Seth
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (03): : 235 - 241
  • [39] PHARMACOKINETIC INTERACTIONS BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND SIROLIMUS IN HEALTHY SUBJECTS
    Hulskotte, E. G.
    Feng, H. -P.
    Xuan, F.
    Lin, W.
    Zhu, Y.
    Rasmusen, S.
    Butterton, J. R.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S190 - S190
  • [40] Conversion to sirolimus in renal transplant patients with tumors
    Sanchez-Fructuoso, A.
    Conesa, J.
    Flores, I. Perez
    Ridao, N.
    Calvo, N.
    Prats, D.
    Rodriguez, A.
    Barrientos, A.
    TRANSPLANTATION PROCEEDINGS, 2006, 38 (08) : 2451 - 2452